Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Study ID
NCT02568267

Study type
Interventional

Study phase
Phase 2

Study status
Active, not recruiting

Trial Acronym

STARTRK-2

Trial Summary

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

More informations

Trial Starting Date

Nov 19,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

534